Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | RBP4 | P02753 | 4/20 | 0.39 |
| ▸ | TTR | P02766 | 3/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060059 | 0.91 | SYK (0.47) | CCNE1CDK2RETSYKSUV39H2 | |
| SCHEMBL10093476 | 0.86 | SYK (0.48) | RETSYK | |
| SCHEMBL10093478 | 0.86 | SYK (0.48) | RETSYK | |
| SCHEMBL10078811 | 0.86 | CCNE1 (0.43) | CCNE1CDK2RETSYKRBP4 | |
| SCHEMBL3786025 | 0.86 | RET (0.49) | CCNE1CDK2RET | |
| SCHEMBL10060052 | 0.84 | RET (0.45) | CCNE1CDK2RETRBP4TTR | |
| SCHEMBL10060060 | 0.79 | RET (0.56) | CCNE1CDK2RETSYK | |
| SCHEMBL10093483 | 0.79 | AURKA (0.38) | CCNE1CDK2RETSYK | |
| SCHEMBL10093482 | 0.79 | AURKA (0.38) | CCNE1CDK2RETSYK | |
| SCHEMBL14678841 | 0.79 | AURKA (0.38) | CCNE1CDK2RETSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492397-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | CCNE1 80/4885CDK2 92/4885RET 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.